"[This] shows a different approach for detecting circulating tumor DNA in bladder cancer patients, and it opens up the possibility for other biorepositories that have serum samples to also enter the ctDNA research environment," says Richard T. Bryan, MBChB, PhD, MRCS, FacadTM.

Investigators will begin setting up the TRANSFORM trial in spring 2024, with study recruitment set to begin later in the year

The test, which was launched in Canada in September 2023, is available through Nanostics’ accredited laboratory in Edmonton, Alberta.

"We felt that it was important to again address this topic because we have received numerous questions regarding the correct use of this code and we have had some experience using the code now that it is active and been able to observe some of the initial payment processing by the payer," write Jonathan Rubenstein, MD, and Mark Painter.

"Results from these trials show that giving physicians an alert informing them of their patient’s actual risk for antibiotic resistance can help them choose the best antibiotic and reduce extended-spectrum antibiotic use,” says Shruti Gohil, MD, MPH.

All patients have been successfully dosed in the first cohort of patients, and the Safety Review Committee has granted approval for progression of the study to the second dose level of INKmune.

"The results showed the contemporary Aquablation procedural safety in Japanese men is exceptional in a broad range of prostate sizes along with significant symptom reduction," says Nobuyuki Hinata, MD.

"This was a very special moment, delivering the news to this patient that his cancer is now undetectable following the treatment with 2 doses of 8 GBq of 67Cu-SAR-bisPSMA," says Luke Nordquist, MD, FACP.

A late phase 3 trial evaluating the agent is underway at several clinics in Europe.

“This clinical study has the potential to demonstrate the value of Chimeric Antigen Receptor (CAR) T cell therapy in solid cancers such as kidney cancer with a high unmet medical need,” said Abla Creasey, PhD.

The first patient was treated with TLX250-CDx at the Olivia Newton-John Cancer Wellness Centre at Austin Health in Melbourne, Australia,

"It is important as a field that we recognize the potential emotional impact of surgical adverse events," writes Amy N. Luckenbaugh, MD.

Following the positive recommendation, the European Commission will now review the application for vibegron for potential approval in the OAB setting in all EU member states, as well as in Iceland, Liechtenstein, and Norway.

"There are opportunities for doctors to become more productive, to see more patients, and to avoid the erosion of their incomes," writes Neil Baum, MD.

"I think in terms of the 2 large tool sets we have, biomarker testing through urine or blood tests and imaging. I think both are only going to get better," says Jeffrey Tosoian, MD, MPH.

Petros also announced that it has received positive feedback from the FDA after the agency’s informal review of Petros’ technology component for self-selection.

The clearance of the IND application for RAG-01 will initiate the launch of clinical trials in the US.

A decision regarding EU marketing authorization is expected by June 2024.

“ARO-HIF2’s ability to target cancer cells, disrupting a key tumor-driving mechanism, illustrates the potential of siRNA technology in oncology,” says James Brugarolas, MD, PhD.

Dean S. Elterman, MD, MSc, FRCSC, highlights several studies in BPH being presented at the 2024 AUA Annual Meeting.

"And [3 out of 5] of those patients who were initially deemed to go on to nephroureterectomy were able to be converted to endoscopic management," says Surena F. Matin, MD.

“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.

The approval is based on 3 clinical trials evaluating the efficacy of different pivmecillinam dosing regimens in comparison with either placebo, another oral antibacterial drug, or ibuprofen.

Adam B. Weiner, MD, highlights several studies in prostate cancer set to be presented at the upcoming 2024 American Urological Association Annual Meeting.

The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.